Sinovac Biotech Stock Gross Profit
Sinovac Biotech fundamentals help investors to digest information that contributes to Sinovac Biotech's financial success or failures. It also enables traders to predict the movement of Sinovac Stock. The fundamental analysis module provides a way to measure Sinovac Biotech's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Sinovac Biotech stock.
Sinovac |
Sinovac Biotech Company Gross Profit Analysis
Sinovac Biotech's Gross Profit is the most basic measure of business operational efficiency. It is simply the difference between sales revenue and the cost associated with making a product or providing a service. It is calculated before deducting administrative expenses, taxes, and interest payments.
Current Sinovac Biotech Gross Profit | 213.58 M |
Most of Sinovac Biotech's fundamental indicators, such as Gross Profit, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Sinovac Biotech is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Gross Profit varies significantly from one sector to another and tells an investor how much money a business would have made if it didn't have to pay any overhead expenses such as salary, taxes, or rent.
CompetitionAccording to the company disclosure, Sinovac Biotech reported 213.58 M of gross profit. This is 90.48% lower than that of the Healthcare sector and 77.53% lower than that of the Biotechnology industry. The gross profit for all United States stocks is 99.22% higher than that of the company.
Sinovac Gross Profit Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Sinovac Biotech's direct or indirect competition against its Gross Profit to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Sinovac Biotech could also be used in its relative valuation, which is a method of valuing Sinovac Biotech by comparing valuation metrics of similar companies.Sinovac Biotech is currently under evaluation in gross profit category among related companies.
Sinovac Fundamentals
| Return On Equity | 11.03 | ||||
| Return On Asset | 4.53 | ||||
| Profit Margin | 10.02 % | ||||
| Operating Margin | 15.86 % | ||||
| Current Valuation | 614.58 M | ||||
| Shares Outstanding | 98.9 M | ||||
| Shares Owned By Insiders | 15.89 % | ||||
| Shares Owned By Institutions | 23.11 % | ||||
| Number Of Shares Shorted | 199.77 K | ||||
| Price To Earning | 48.65 X | ||||
| Price To Book | 2.29 X | ||||
| Price To Sales | 2.16 X | ||||
| Revenue | 213.17 M | ||||
| Gross Profit | 213.58 M | ||||
| EBITDA | 38.49 M | ||||
| Net Income | 15.35 M | ||||
| Cash And Equivalents | 176.72 M | ||||
| Cash Per Share | 1.79 X | ||||
| Total Debt | 93.13 M | ||||
| Debt To Equity | 0.28 % | ||||
| Current Ratio | 2.98 X | ||||
| Book Value Per Share | 2.83 X | ||||
| Cash Flow From Operations | 22.17 M | ||||
| Short Ratio | 47.51 X | ||||
| Earnings Per Share | 0.13 X | ||||
| Number Of Employees | 910 | ||||
| Beta | 0.08 | ||||
| Market Capitalization | 460.25 M | ||||
| Total Asset | 202.98 M | ||||
| Retained Earnings | (8.28 M) | ||||
| Working Capital | 70.52 M | ||||
| Current Asset | 128.52 M | ||||
| Current Liabilities | 58 M | ||||
| Z Score | 3.4 |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Sinovac Biotech in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Sinovac Biotech's short interest history, or implied volatility extrapolated from Sinovac Biotech options trading.
Currently Active Assets on Macroaxis
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real. You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
Other Consideration for investing in Sinovac Stock
If you are still planning to invest in Sinovac Biotech check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Sinovac Biotech's history and understand the potential risks before investing.
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio |